Pulmonary arterial hypertension is known to be related to worse prognosis in patients with heart failure (HF). Quantification of pulmonary vascular resistance (PVR) still requires invasive right heart catheterization. Recent studies have shown an accurate method for non-invasive estimation of PVR by cardiac magnetic resonance (CMR). Our aim was to evaluate the prognostic value of PVR calculated by CMR in patients with congestive HF.
Introduction
Pulmonary hypertension (PH) has been associated with poor prognosis in patients with chronic heart failure (HF).
1,2 Although estimation of systolic pulmonary arterial pressure (sPAP) by Doppler echocardiography is widely used in clinical practice, the inconsistency of this method is well known. 3 Therefore, despite of radiation exposure and associated risks of the procedure, right heart catheterization is still the gold standard for establishing a diagnosis of PH. Cardiac magnetic resonance (CMR) allows the evaluation of both right ventricular and pulmonary artery (PA) anatomy and function and establishes the presence of late gadolinium enhancement (LGE), which has been associated with adverse events in PH. 4 In addition, CMR has recently proved to be an accurate technique for noninvasive estimation of pulmonary vascular resistance (PVR), 5, 6 which is a key variable in diagnosis, risk stratification, and follow-up of patients with PH. Furthermore, based on solid evidence supporting the prognostic value of LGE area and left ventricular volumes and systolic function estimated by CMR in patients with chronic HF, 7 -10 we sought to assess the role of PVR calculated by CMR to predict adverse cardiovascular outcomes in patients with chronic HF recently admitted for acute decompensation.
Methods

Study population
We prospectively enrolled 132 consecutive patients (mean age 65.6 + 13.1 years, 69% male) referred to our cardiac imaging unit between March 2011 and January 2014. All patients were recently admitted for acute decompensated HF in different hospitals of the reference area and underwent a CMR study under clinician criterion for the evaluation of known or suspected chronic HF. Diagnosis of HF was carried out as directed by current guidelines. 1, 9 Written informed consent was obtained before CMR in each patient.
Clinical variables
Medical history was examined in all patients, recording cardiovascular risk factors and medication. Relevant blood test values [including haemoglobin, creatinine, and N-terminal pro-brain natriuretic hormone (NT-proBNP) at admission] were also recorded as well as significant electrocardiographic parameters (as duration of QRS complex and the presence of atrial fibrillation or left bundle branch block).
Coronary angiography
All patients underwent cardiac catheterization at our institution as referral hospital during current admission or previously. Data from coronariography were recorded to define ischaemic aetiology of HF according to Felker et al. 10 criteria: history of myocardial infarction or revascularization; ≥75% stenosis of left main or proximal left anterior descending artery; or ≥75% stenosis of two or more epicardial vessels.
Echocardiography
Echocardiographic data for analysis were recorded from studies during admission. Left ventricular ejection fraction (LVEF), left ventricular enddiastolic and end-systolic diameters, tricuspid annular plane systolic excursion, E/e' ratio, and sPAP were examined, although LVEF was the only parameter recorded in medical history in all patients. The other variables were considered when available.
Cardiac magnetic resonance
CMR was performed with a 1.5T unit (Magneton Sonata, Siemens, Erlangen, Germany). For cine imaging, breath-holding electrocardiogram (ECG)-gated steady-state free precession (SSFP) sequences were used as normally to acquire long-and short-axis slices and hence evaluate ventricular volumes and function. A standard 17-segmented cardiac model was used for segmentation and assessing areas of late gadolinium images, 11 acquired after intravenous injection (0.15 mL/kg) of dimeglumine gadobenate 0.5 M. The areas of necrosis or fibrosis were assessed using inversion-recovery SSFP sequences (repetition time 2.9-3.9 ms, echo time 1.5 -2.0 ms, flip angle 45 -908, slice thickness 6 mm with interslice gap 4 mm, in-plane spatial resolution 1.5-2 mm, temporal resolution 35 -45 ms) 10 min after contrast administration adjusting the inversion time (between 250 -300 ms generally) to null normal myocardium. Flow imaging was performed perpendicular to the PA trunk with a velocity-encoded gradient echo sequence. Two doubleoblique orthogonal views oriented along the main PA were acquired with SSFP cine sequence and used as the reference to prescribe the plane perpendicular to the PA trunk for the acquisition of phase contrast images. These parameters were applied as usually: repetition time/echo time 5.9-7.5/3.1-6.5 ms, slice thickness 6 mm, in-plane resolution 1.5 -3 mm, 20 reconstructed cardiac phases, and temporal resolution 55 -105 ms. 4, 5 Images were analysed using a specific software (Argus w , Siemens). Short-axis slices were used to calculate ejection fractions and ventricular volumes using Simpson's method. LGE of the myocardium was visually identified by a CMR expert blinded to haemodynamic and echocardiographic data, considering both the presence (ischaemic and nonischaemic patterns) as distribution of LGE (number of myocardial segments with LGE). PA cross-section was outlined in each cardiac phase to estimate PA area and flow and calculate peak velocity, average velocity during the complete cardiac cycle, minimum and maximum areas, and PA net forward volume. Both ventricular volumes and PA area were adjusted to body surface area ( Figure 1) .
We 
Clinical follow-up
Readmission for HF and all-cause mortality were considered as major adverse events at follow-up. Combination of both outcomes was pondered as primary endpoint. Data were collected from electronic centralized medical history and shared by all hospitals involved.
Statistical analysis
Categorical values were expressed as absolute number and percentages, and continuous variables as mean + standard deviation. KolmogorovSmirnov test was used to test for normality of the distribution. Patients were divided in two groups according to the optimal cut-off value of PVR calculated by receiver operating characteristic (ROC) curve to predict primary endpoint at follow-up. Comparisons between both groups were made by x 2 test or unpaired Student's t-test as appropriate.
A multivariate Cox regression model was performed with all variables with a P-value of ,0.10 in the univariate analysis. Survival curves for PVR and presence of LGE on CMR, as two significant variables in multivariate analysis, were constructed with the Kaplan -Meier method and compared by means of the Log-Rank test.
All tests were two-tailed, and a P-value of ,0.05 was considered statistically significant. Statistical analyses were performed using SPSS w software (version 17.0).
Results
Baseline patient characteristics according to PVR
Baseline characteristics of patients are presented in Table 1 . We found a study population optimally medicated, with mean LVEF 35.0 + 15.4% by CMR, 39% with ischaemic aetiology of HF, and 24% of patients with atrial fibrillation.
Patients were divided in two groups according to the value of PVR estimated by CMR. Thereby, the optimal cut-off value of PVR calculated by ROC curve to predict total adverse events, defined as readmission for HF and all-cause mortality, was 5. 
Echocardiography and CMR parameters in both groups of patients
As expected, we found worse ventricular function and higher ventricular diameters and volumes in patients with elevated PVR, both with echocardiography as with CMR ( Table 2) . A significant increase of sPAP by echocardiography was also observed in these patients (47.4 + 17.5 vs. 37.4 + 13.9 mmHg, P ¼ 0.04; based on available data).
Univariate analysis
Univariate analysis of all cardiovascular risk factors and parameters of echocardiography and CMR are reported in Table 3 . PVR was statistically significant for predicting total adverse event at follow-up. Other significant univariate predictors for adverse outcome were the presence of atrial fibrillation and the following CMR parameters: LVEF, RVEF, and left ventricular end-diastolic volume indexed to body surface.
Prognosis impact of PVR estimated by CMR
Patients with primary endpoint on long-term follow-up had higher values of PVR calculated by CMR (6.77 + 1.9 vs. 4.1 + 1.6 Wu, P , 0.001). In order to assess whether the value of PVR had independently prognostic impact, a Cox proportional hazard analysis was performed including all factors in univariate analysis with P , 0.10 ( Table 4 
Kaplan -Meier survival analysis
At a mean follow-up of 10.3 (1-35) months, patients with PVR ≥5.2 Wu had a significantly worse prognosis, as indicated in Kaplan -Meier survival curves, both for readmission to HF (Log-Rank test, P , 0.001) as for all-cause mortality (Log-Rank test, P ¼ 0.049) and risk to reach the primary endpoint (Log-Rank test, P , 0.001) (Figure 3) .
Kaplan-Meier curves of presence of LGE as the other independent predictor on multivariate analysis were also generated, as shown in Figure 4 . Although patients with presence of LGE on CMR were also statistically more likely to reach the primary endpoint than those without LGE (Log-Rank test, P ¼ 0.029), no differences on readmission for HF were found when separately analysed. Cardiac events during follow-up in these patients, both dividing the sample by PVR as by the presence of LGE on CMR, are summarized in Table 5 .
Interestingly, the prognostic value of PVR remained significant both in patients with reduced and preserved systolic function, considering LVEF ≥50% as cut-off. 12 Kaplan-Meier curves are represented in Figure 5 .
Discussion
To our knowledge, this is the first study that assesses the prognostic impact of high PVR estimated by CMR in patients with chronic HF. After recent studies that showed diagnosis accuracy of CMR for non-invasive calculation of PVR, we sought to evaluate the role of this measure on risk stratification of HF patients, and we found that increased PVR by CMR was an independent predictor of worse prognosis at long-term follow-up, both for HF readmission as for all-cause mortality. The measurement of this parameter could, therefore, provide additional valuable prognostic information if included routinely in CMR protocol for patients with HF. In current clinical practice, echocardiography is still firstly used to evaluate right ventricular function and volumes and to estimate sPAP, which is calculated indirectly by the velocity of the tricuspid regurgitant jet, based on classical studies that correlated these echocardiographic measures with those from right heart catheterization. 13, 14 However, inconsistency of this method is well known, because of inter-and intra-operator variability, and dependence of the degree of tricuspid regurgitation. For these reasons, some other studies have sought to assess the estimation of PVR by echocardiography, as more reliable variable in patients with PH, although with controversial results. 15 -17 Additionally, other parameters have been evaluated, such as PA acceleration time or right ventricular isovolumic relaxation time, even if they are systematically neglected in routine practice because of the arduousness of calculation. 18, 19 In our study with data recorded from real clinical practice, in fact, sPAP could be calculated only in 49 patients, either because there was no significant tricuspid regurgitation or because the echocardiographic acoustic window did not allow it. In recent years, several studies have demonstrated the feasibility of CMR to estimate PVR in patients with suspected PH. 4, 5 We used the model proposed by García-Alvarez et al., 20 which was validated in 100 patients using only two variables in the formula: PA average velocity and RVEF. This model confirmed a high accuracy to detect increased PVR and also allowed for monitoring of acute and chronic changes in PVR. Therefore, it could become an ideal non-invasive modality for the assessment and follow-up of patients with PH.
In patients with HF, in which CMR is frequently used to define aetiology, clinical management, and prognostic stratification, regular measurement of PVR could add reliable information in this regard. So, in order to assess the potential prognostic role of this value in patients recently admitted for acute decompensated HF, all patients referred to our cardiac imaging unit were long-term followed. After determination of optimal cut point for PVR to predict adverse events using ROC curve, we found that patients with increased PVR had worse left and right ventricular systolic function and higher volumes, as expected. In the context of patients with HF probably more advanced was also found more prevalence of atrial fibrillation, more patients treated with aldosterone antagonists, and higher values of NT-proBNP on admission.
Accordingly, with these more severe patients, high PVR was associated with the primary endpoint at follow-up. The main body of events was represented by readmissions for HF (40 total adverse events, 37 readmissions for HF, 9 deaths), probably owing to small sample and mean follow-up period of only 10 months. Of the total nine fatal events, six had also been previously admitted for HF, suggesting that these were patients with a progressed disease. Thereby, when we analyse mortality causes, we found three sudden cardiac deaths, three deaths for major bleeding in atrial fibrillation patients, two cardiac deaths for decompensated HF, and one death for sepsis with multiple organ dysfunction. It should be noted that just because of this limited follow-up with few events, all-cause mortality was considered in survival analyses. Interestingly, only two variables remained as independent predictors in survival analyses: PVR ≥5.2 Wu and the presence of LGE on CMR. Thereby, while the prognostic value of LGE in patients with HF is firmly established 6 -8,21 and has even reflected in current guidelines, 1,9 the potential role of PVR estimated by CMR in predicting adverse events in these patients had not been previously evaluated. In our study, although both variables were significant in multivariate Cox regression analysis, only high PVR behaved as a predictor in all Kaplan -Meier curves. Furthermore, it should be noted that the percentage of patients with LGE on CMR was comparable between both groups according to PVR, which highlights the independent value of high PVR over the presence of LGE. Another salient result of this study suggests that prognostic value of PVR appears to be kept up regardless of LVEF. Thus, considering two groups according to preserved or reduced systolic function, we found that in the small number of patients with LVEF ≥50%, PVR remained as an independent predictor of adverse events at follow-up, reinforcing the potential value of this CMR measures in the wide spectrum of patients with HF.
Prognostic importance of PH in chronic HF is well documented. 22, 23 Nonetheless, diagnosis is still challenging in clinical practice, due to inconsistency of echocardiography and risks derived from right heart catheterization. The combined use of two variables with established prognostic value as RVEF and PA average velocity 24, 25 estimated by CMR allows simple and reliable calculation of PVR. As well as assessment of LGE on CMR has become an essential tool in HF patients for clinical management in lasts years, among other variables such as LVEF, QRS duration, or New York Heart Association functional class, our results suggest that inclusion of PVR measurement in standard protocol could contribute to prognosis stratification of patients with HF.
Limitations
The main limitation of the study is determined by the process of enrolling patients and subsequent analysis of clinical and echocardiographic data. Although inclusion was prospective, patients came referred from different centres to our cardiac imaging unit and thus, there was no protocol on data record regarding blood tests, echocardiography, or clinical management. This caused data loss in some important variables such as NT-proBNP on admission or echocardiographic parameters. In this respect, we should note that since natriuretic peptides were recorded only from 52 patients, this variable was not included in univariate or multivariate analysis. Neither were included some echocardiographic variables for the same reason.
Since right heart catheterization is still the reference test for diagnosis and follow-up of patients with PH, the absence of haemodynamic data could also be considered a limitation of the study.
Other important limitations are the reduced size of study population, the limited follow-up period, and the fact of considering allcause mortality, rather than cardiac mortality, as fatal event in the primary endpoint. Further studies are therefore necessary to consolidate the prognostic value of PVR by CMR in patients with HF.
Conclusion
Non-invasive estimation of PVR by CMR might be useful for risk stratification of patients with chronic HF, irrespective of aetiology, or LVEF.
